Max Kennerly on Nostr: These similarities apply just as much to GLP-1s. There's certainly more aggressive ...
These similarities apply just as much to GLP-1s. There's certainly more aggressive competition among drugmakers to produce and market GLP-1s, whereas the bulk of ADHD drugs are low-profit generics.
So are we going to arbitrarily limit them too, or just ADHD drugs?
Published at
2024-04-19 17:29:03Event JSON
{
"id": "07c78da21d3d181363e436aa1e402c951c1c48028adbed0d2ae20956089a000a",
"pubkey": "829aaedb25e99e41d5f5af93828c60432cadb0e96457a58b5b146db870d08bbd",
"created_at": 1713547743,
"kind": 1,
"tags": [
[
"e",
"b59fe15a11e3ddd9c9d2d84e6a2794369bcf8264ecef3970827840ee26cd7574",
"wss://relay.mostr.pub",
"reply"
],
[
"proxy",
"https://mstdn.social/users/maxkennerly/statuses/112299064937097557",
"activitypub"
]
],
"content": "These similarities apply just as much to GLP-1s. There's certainly more aggressive competition among drugmakers to produce and market GLP-1s, whereas the bulk of ADHD drugs are low-profit generics.\n\nSo are we going to arbitrarily limit them too, or just ADHD drugs?\n\nhttps://media.mstdn.social/media_attachments/files/112/299/059/581/842/917/original/fd2b3a92c9918c3c.png",
"sig": "cbf39a87cb9486df46c3c5016beb61cc0d64d1c97595ba2b97d57c3acc0f8879785f191dfdbaddb05b5d3b378dc562a5f828d384d2a525539e2686c3130f4135"
}
